2004
Weight and Leptin Changes Among Risperidone-Treated Youths With Autism: 6-Month Prospective Data
Martin A, Scahill L, Anderson GM, Aman M, Arnold LE, McCracken J, McDougle CJ, Tierney E, Chuang S, Vitiello B. Weight and Leptin Changes Among Risperidone-Treated Youths With Autism: 6-Month Prospective Data. American Journal Of Psychiatry 2004, 161: 1125-1127. PMID: 15169706, DOI: 10.1176/appi.ajp.161.6.1125.Peer-Reviewed Original Research
2003
Which SSRI? A Meta-Analysis of Pharmacotherapy Trials in Pediatric Obsessive-Compulsive Disorder
Geller DA, Biederman J, Stewart SE, Mullin B, Martin A, Spencer T, Faraone SV. Which SSRI? A Meta-Analysis of Pharmacotherapy Trials in Pediatric Obsessive-Compulsive Disorder. American Journal Of Psychiatry 2003, 160: 1919-1928. PMID: 14594734, DOI: 10.1176/appi.ajp.160.11.1919.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsObsessive-compulsive disorderStandardized mean differenceOutcome measuresMean differenceStudy designSerotonin reuptake inhibitorsDependent outcome measuresAdolescent obsessive-compulsive disorderSystematic literature searchMultivariate regression analysisPediatric obsessive-compulsive disorderTypes of drugsEffect sizePlacebo treatmentMedication trialsReuptake inhibitorsOutcome scoresPharmacological treatmentPharmacotherapy trialsOverall effect sizeInclusion criteriaClinical careDrug effectsMeta-AnalysisFrontostriatal Abnormalities in Adolescents With Bipolar Disorder: Preliminary Observations From Functional MRI
Blumberg HP, Martin A, Kaufman J, Leung HC, Skudlarski P, Lacadie C, Fulbright RK, Gore JC, Charney DS, Krystal JH, Peterson BS. Frontostriatal Abnormalities in Adolescents With Bipolar Disorder: Preliminary Observations From Functional MRI. American Journal Of Psychiatry 2003, 160: 1345-1347. PMID: 12832254, DOI: 10.1176/appi.ajp.160.7.1345.Peer-Reviewed Original ResearchConceptsBipolar disorder groupBipolar disorderHealthy groupComparison subjectsDisorder groupNormal comparison subjectsAdult bipolar disorderHealthy comparison subjectsPresence of dysfunctionFunctional magnetic resonance imagingMagnetic resonance imagingBipolar disorder subjectsAge-related increaseEvent-related functional magnetic resonance imagingFrontostriatal abnormalitiesLeft putamenFunctional abnormalitiesPrefrontal abnormalitiesDepressive symptomsResonance imagingVentral striatumFrontostriatal circuitsDisorder subjectsFunctional MRIDevelopmental disturbancesPsychiatric Inpatient, Outpatient, and Medication Utilization and Costs Among Privately Insured Youths, 19972000
Martin A, Leslie D. Psychiatric Inpatient, Outpatient, and Medication Utilization and Costs Among Privately Insured Youths, 19972000. American Journal Of Psychiatry 2003, 160: 757-764. PMID: 12668366, DOI: 10.1176/appi.ajp.160.4.757.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdolescent Health ServicesAge FactorsAmbulatory CareChildDrug CostsDrug UtilizationFemaleHealth Benefit Plans, EmployeeHealth Care CostsHealth Care SurveysHospitalizationHumansInsurance, PsychiatricLength of StayMaleManaged Care ProgramsMental DisordersMental Health ServicesPsychotropic DrugsUnited StatesUtilization ReviewConceptsOutpatient visitsPsychotropic medicationsProportion of youthOutpatient mental health servicesAnxiety disordersMedication-related costsOutpatient treatment modalityUse of inpatientTreatment of depressionInpatient psychiatric admissionAnalysis of inpatientMental health servicesAge 17 yearsAnnual utilization ratesMedication utilizationPharmacy claimsOutpatient costsTreatment modalitiesPsychiatric admissionsAnnual inpatientAdjustment disorderInpatient daysInpatientsHealth servicesPsychiatric inpatients
2002
Effects of Development on Olanzapine-Associated Adverse Events
WOODS SW, MARTIN A, SPECTOR SG, MCGLASHAN TH. Effects of Development on Olanzapine-Associated Adverse Events. Journal Of The American Academy Of Child & Adolescent Psychiatry 2002, 41: 1439-1446. PMID: 12447030, DOI: 10.1097/00004583-200212000-00015.Peer-Reviewed Original ResearchConceptsLiver function abnormalitiesAdverse eventsFunction abnormalitiesAtypical antipsychoticsComplaint riskWeight gainAtypical antipsychotic medicationsExtrapyramidal syndromeTardive dyskinesiaProlactin increaseAntipsychotic medicationAdolescent patientsRisk ratioPatient exposureSurveillance databaseAge groupsOlanzapineComplaintsConfidence intervalsExposure estimatesAntipsychoticsSedationPatientsChildrenAdults
2001
Methodological Issues in Designing a Multisite Trial of Risperidone in Children and Adolescents with Autism
Scahill L, McCracken J, McDougle C, Aman M, Arnold L, Tierney E, Cronin P, Davies M, Ghuman J, Gonzalez N, Koenig K, Lindsay R, Martin A, McGough J, Posey D, Swiezy N, Volkmar F, Ritz L, Vitiello B. Methodological Issues in Designing a Multisite Trial of Risperidone in Children and Adolescents with Autism. Journal Of Child And Adolescent Psychopharmacology 2001, 11: 377-388. PMID: 11838820, DOI: 10.1089/104454601317261555.Peer-Reviewed Original ResearchConceptsPlacebo-controlled studyPlacebo-controlled discontinuation studyAutistic disorderSafety of risperidoneStudy of RisperidoneStandard pharmacological treatmentSelf-injurious behaviorDiscontinuation studyPharmacological treatmentClinical trialsInclusion criteriaLong-term effectsSevere tantrumsTrial designClinical relevanceClinical practiceLength of trialRisperidoneMultisite trialStudy designContinuous treatmentTrialsTreatment effectsDisordersMaintenance phase
2000
The use of psychotropic medications in young children: the facts, the controversy, and the practice.
Stubbe DE, Martin A. The use of psychotropic medications in young children: the facts, the controversy, and the practice. Connecticut Medicine 2000, 64: 329-33. PMID: 10909194.Peer-Reviewed Original Research